Abstract
Background: Oral anticoagulation (OAC) is the most effective treatment to prevent strokes in patients with atrial fibrillation (AF). Many older patients are not prescribed OAC. Objective: To explore which co-morbid conditions in older patients with AF have been associated with under-treatment with OAC, or were used as exclusion criteria for trials, or have been associated with increased risk of bleeding. Methods: A Pubmed search was conducted with the terms elderly, atrial fibrillation, stroke risk, bleeding risk, intracranial haemorrhage, cognition, fall risk, renal dysfunction, alcohol abuse, malignancy, polypharmacy, NSAID, under-treatment, under-use and under-prescription. Results: Higher age is associated with under-treatment. Patients with a higher risk of stroke show higher rates of bleeding complications. The associations of bleeding rates with possible contraindications are inconsistent. Discussion: Published bleeding rates reflect selection bias, describing mainly relatively healthy older patients. The use of stratification schemes for stroke risk and for bleeding risk will have to be implemented. Conclusion: The decision to prescribe OAC in older patients with AF remains a challenging task since bleeding risk is difficult to estimate reliably. Stratification schemes may be helpful.
Keywords: Geriatric, elderly, atrial fibrillation, under-treatment, anticoagulation, contraindications, major bleeding risk
Current Drug Safety
Title: Contraindications for Anticoagulation in Older Patients with Atrial Fibrillation: A Narrative Review
Volume: 5 Issue: 3
Author(s): Linda R. Tulner, Ingeborg M.J.A. Kuper, Jos P.C.M. van Campen, Melvin R. Mac Gillavry, Vincent I.H. Kwa, Cornelis H.W. Koks, Jos H.Beijnen and Desiderius P.M. Brandjes
Affiliation:
Keywords: Geriatric, elderly, atrial fibrillation, under-treatment, anticoagulation, contraindications, major bleeding risk
Abstract: Background: Oral anticoagulation (OAC) is the most effective treatment to prevent strokes in patients with atrial fibrillation (AF). Many older patients are not prescribed OAC. Objective: To explore which co-morbid conditions in older patients with AF have been associated with under-treatment with OAC, or were used as exclusion criteria for trials, or have been associated with increased risk of bleeding. Methods: A Pubmed search was conducted with the terms elderly, atrial fibrillation, stroke risk, bleeding risk, intracranial haemorrhage, cognition, fall risk, renal dysfunction, alcohol abuse, malignancy, polypharmacy, NSAID, under-treatment, under-use and under-prescription. Results: Higher age is associated with under-treatment. Patients with a higher risk of stroke show higher rates of bleeding complications. The associations of bleeding rates with possible contraindications are inconsistent. Discussion: Published bleeding rates reflect selection bias, describing mainly relatively healthy older patients. The use of stratification schemes for stroke risk and for bleeding risk will have to be implemented. Conclusion: The decision to prescribe OAC in older patients with AF remains a challenging task since bleeding risk is difficult to estimate reliably. Stratification schemes may be helpful.
Export Options
About this article
Cite this article as:
R. Tulner Linda, M.J.A. Kuper Ingeborg, P.C.M. van Campen Jos, R. Mac Gillavry Melvin, I.H. Kwa Vincent, H.W. Koks Cornelis, H.Beijnen Jos and P.M. Brandjes Desiderius, Contraindications for Anticoagulation in Older Patients with Atrial Fibrillation: A Narrative Review, Current Drug Safety 2010; 5 (3) . https://dx.doi.org/10.2174/157488610791698253
DOI https://dx.doi.org/10.2174/157488610791698253 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Low Activity of Plasminogen Activator: A Common Feature of Non- Iatrogenic Comorbidities of Schizophrenia
CNS & Neurological Disorders - Drug Targets Stacking Regression Algorithms to Predict PM<sub>2.5</sub> in the Smart City Using Internet of Things
Recent Advances in Computer Science and Communications Gene Expression Analysis Approach to Establish Possible Links Between Parkinson's Disease, Cancer and Cardiovascular Diseases
CNS & Neurological Disorders - Drug Targets Editorial: Do Some Glucagon-Like-Peptide-1 Receptor Agonists (GLP-1 RA) Reduce Macrovascular Complications of Type 2 Diabetes Mellitus? (A Commentary on the Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER) Trial)
Current Vascular Pharmacology Variation of Antioxidant Capacity in Different Layers of Onion (Allium cepa L.) At Two Different Stages of Maturation
Current Nutrition & Food Science Update on Glycoprotein IIb/IIIa: Role in Primary Coronary Intervention
Cardiovascular & Hematological Agents in Medicinal Chemistry Impaired Insulin Sensitivity and Secretion in Patients with Alzheimer’s Disease: The Relationship with Other Atherosclerosis Risk Factors
Current Vascular Pharmacology Nanodiagnostic Attainments and Clinical Perspectives on C-Reactive Protein: Cardiovascular Disease Risks Assessment
Current Medicinal Chemistry The Immunoproteasome as a Therapeutic Target for Hematological Malignancies
Current Cancer Drug Targets Editorial [(Poly)phenol Chemistry: Part II - Physicochemical Properties & Biological Implications (Guest Editor: Stefan Chassaing)]
Current Organic Chemistry Interrupting the Natural History of Diabetes Mellitus: Lifestyle, Pharmacological and Surgical Strategies Targeting Disease Progression
Current Vascular Pharmacology 1,8-Naphthyridine Derivatives: A Privileged Scaffold for Versatile Biological Activities
Mini-Reviews in Medicinal Chemistry Impact of Prone Position on Myocardial Perfusion SPECT Interpretation in Women with Suspected Coronary Disease
Current Medical Imaging Screening the Receptorome Yields Validated Molecular Targets for Drug Discovery
Current Pharmaceutical Design The Etiology of Hypertension in the Metabolic Syndrome Part One: An Introduction to the History, the Concept and the Models
Current Vascular Pharmacology Secondary Prevention of Ischemic Stroke
Current Drug Targets The Fabry Cardiomyopathy - Diagnostic Approach and Current Treatment
Current Pharmaceutical Design Lentiviral Vectors: A Versatile Tool to Fight Cancer
Current Molecular Medicine Wharton’s Jelly or Bone Marrow Mesenchymal Stromal Cells Improve Cardiac Function Following Myocardial Infarction for More Than 32 Weeks in a Rat Model: A Preliminary Report
Current Stem Cell Research & Therapy Pleiotropic Effects of Glucagon-like Peptide-1 (GLP-1)-Based Therapies on Vascular Complications in Diabetes
Current Pharmaceutical Design